Abstract

Multiple myeloma combined with nephropathy is one main cause of death in patients; we started this study to discuss the clinical efficacy and incidence of adverse effects of lenalidomide combined with bortezomib in multiple myeloma nephropathy treatment. We randomly selected eighty multiple myeloma nephropathy patients in Hematology Department of the First People’s Hospital of Taizhou City from March 2020 to September 2021, then divided them into observation group (40 cases received lenalidomide combined with bortezomib treatment) and control group (40 cases received bortezomib treatment). Compared both groups on serum immunoglobulin, light chain protein concentration, blood creatinine, blood uric acid and nephropathy before and after therapy and also compared the clinical efficiency and the occurrence of adverse reactions. Observation group possessed remarkably higher clinical efficiency (92.5 %) than control group (82.5 %) (p<0.05); it possessed obviously smaller decrease of immunoglobulin, light chain protein concentration level, serum creatinine, blood calcium and blood uric acid than control group (p<0.05); its adverse reactions occurrence (17.5 %) had no obvious dereference from control group (20.0 %) (p<0.05); its adverse reactions rate (17.5 %) had no obvious dereference from control group (20.0 %) (p<0.05). Lenalidomide combined with bortezomib has better clinical efficacy in treating multiple myeloma nephropathy, can effectively improve renal function, has greater clinical efficacy and does not increase adverse reactions rate, so it is worth popularizing in clinic.